Overview of Катадолон

What is Катадолон (Flupirtine)?

The drug Катадолон (Katadolon) is a prescription-only medicine distinguished by its unique action on the central nervous system to provide pain relief.

Property	Description
Active ingredient	Flupirtine (or Flupirtine maleate)
Form	Capsules (IR/MR), Suppositories, Solution for injection
Pharmacological class	Centrally Acting Non-Opioid Analgesic (SNEPCO)
Common use	Pain relief, especially when associated with muscle tension
Origin	Synthetic (Aminopyridine derivative)

What Type of Analgesic is Катадолон (Flupirtine)?

Катадолон utilizes the active ingredient Flupirtine, which is classified as a Centrally Acting Non-Opioid Analgesic and is the first representative of a class known as Selective Neuronal Potassium Channel Openers (SNEPCOs). This chemical distinction sets it apart from both opioids and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), as it is devoid of anti-inflammatory effects and does not act through opioid receptors. This unique classification indicates that the medicine provides an alternative mechanism for managing pain when traditional classes are unsuitable or ineffective.

Is Катадолон a Synthetic Compound, and What Forms Are Available?

Flupirtine is a synthetic compound derived from the aminopyridine family and is typically marketed as a single-ingredient product, often as the salt, Flupirtine maleate. Originally developed in Germany in the 1980s, the brand name Katadolon was among the first formulations to gain market approval in Europe. The drug is prepared for various routes of administration, including immediate release capsules, modified release tablets (such as Katadolon Retard), suppositories, and a sterile solution for injection. Although this medicine has been available since the 1980s, it has been noted that Flupirtine is associated with an increased risk of liver toxicity, leading to restrictions on its use.

What is the General Therapeutic Purpose of Flupirtine?

The general purpose of Flupirtine is to provide effective pain relief by stabilizing the over-excitable nerve cells that transmit pain signals. The drug's dual action, which includes an intrinsic muscle relaxation property, is recognized for its utility in managing pain, including that associated with muscle tenseness or spasms. This mechanism, achieved through the activation of specific potassium channels, makes the medicine particularly suitable for managing moderate-to-severe pain where the goal is to reduce central neuronal hyperexcitability and concurrent muscle stiffness.

What side effects are possible with Катадолон?

Possible Side Effects and Safety Information for Катадолон (Flupirtine)

The official safety profile for Flupirtine is critically structured around the potential for severe hepatotoxicity (liver damage), a risk noted in regulatory reviews by the European Medicines Agency (EMA) that has led to strict limitations on use.

Safety Restrictions and Monitoring

To mitigate the risk of serious liver injury, which includes documented cases of acute hepatic failure, the maximum duration of treatment is officially restricted to two weeks for all oral and suppository forms. Mandatory liver function monitoring (e.g., weekly enzyme testing) is required throughout the course of treatment. The medicine is contraindicated in individuals with pre-existing liver disease, hepatic encephalopathy, or cholestasis.

Adverse Reactions Classified by Frequency

Adverse effects are categorized by frequency, affecting several system-organ classes, including the nervous and gastrointestinal systems. Serious adverse reactions are rare but clinically significant.

Classification	Examples of Documented Effects
Very Common	Increased transaminases (liver enzymes)
Common	Dizziness, fatigue, insomnia, nausea, vomiting, dry mouth
Uncommon	Headache, tremor, anxiety, depression, diarrhea, rash, visual disturbances

Serious Adverse Reactions

The most serious documented reactions include Acute Hepatic Failure, Hepatitis, and severe Anaphylactic Reactions. Neurological effects such as dizziness and fatigue are more frequently reported at the beginning of treatment, while the risk of severe liver damage is directly associated with use extending beyond the two-week limit.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary concern in the event of an overdose or excessive exposure to Катадолон (flupirtine) is the risk of severe hepatotoxicity, including potentially fatal acute liver failure (ALF). Regulatory agencies have identified this as the most serious outcome following high exposure or overdose.

Immediate medical assistance is required for any suspected overdose or if symptoms of overdose occur, as early intervention is critical despite the lack of a specific antidote.

Documented Overdose Manifestations

Symptoms reported following overdose have included temporary central nervous system (CNS) effects, which are generally reversible:

Central Nervous System: Unconsciousness, disordered consciousness, and transient CNS excitation.
Cardiovascular: Tachycardia (abnormally fast heart rate).

Serious Outcomes and Management

Outcome	Description as per Regulatory Data
Hepatotoxicity	Severe liver injury, including acute liver failure, sometimes requiring liver transplantation.
Treatment	Management is entirely symptomatic and supportive; no specific antidote is available.
Elimination	For very high doses, procedures like forced diuresis and osmotic diuresis may be considered to help eliminate the drug.

It is imperative to seek urgent medical attention immediately upon suspicion of an overdose, as symptoms may not reflect the severity of the underlying potential for organ damage.

Therapeutic Uses of Катадолон

What Катадолон Treats: Main Uses and Benefits

The core therapeutic application of Катадолон (Flupirtine) is relevant for easing symptoms related to moderate-to-severe pain associated with increased muscle tone or spasm. Its use is considered relevant in clinical settings that involve acute or unstable symptom patterns, and is considered relevant across domains where additional symptomatic support is needed.

This medicine is applied across conditions presenting with systemic or localized discomfort associated with muscle tenseness, which includes manifestations like certain tension headaches, and symptoms related to physical discomfort following trauma or various post-operative procedures. This therapeutic role assists with easing groups of symptoms that involve moderate-to-severe discomfort and related physical tenseness. It is generally used for adults and is considered relevant in situations where patients experience these symptomatic manifestations.

This medicine is applicable within clinical settings that involve acute or disruptive symptom patterns and supports the patient during difficult episodes. It offers symptomatic relief that supports general well-being during symptomatic phases when symptoms are more noticeable.

Quick Fact: Symptomatic Support
This medicine is commonly used to help with acute pain and provides support that contributes to easing the overall symptom load when muscle tenseness is also a factor.

Regulatory References

European Medicines Agency's CMDh position

Eligibility and Restrictions for Use

The official eligibility profile for Катадолон (Flupirtine) is highly restricted and conditional, primarily due to the documented risk of severe liver toxicity (hepatotoxicity). Regulatory documents define who can and cannot use the medicine by establishing strict criteria.

Category	Eligibility Status as per Regulatory Labeling
Permitted Population	Adults with acute pain only, limited to a maximum duration of 14 days. Use is strictly conditional, permitted only when treatment with standard alternatives (NSAIDs, weak opioids) is contraindicated.
Absolute Contraindications	Use is prohibited for patients with pre-existing liver disease, alcohol abuse problems, Myasthenia Gravis, hepatic encephalopathy, cholestasis, or those currently using other hepatotoxic medications.
Age-Group Restrictions	Use is not recommended for children and adolescents under 18 years as safety and efficacy have not been established. Older adults and patients with severe renal impairment require conditional use with a mandated dose reduction.
Conditional Eligibility	Continued eligibility is dependent on weekly liver function monitoring; treatment must be immediately discontinued if abnormal results are found. Safety in pregnancy is not established, and breastfeeding must be stopped if the medicine is used.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Катадолон (Flupirtine) as described in regulatory prescribing information.

Contraindicated Combinations and Organ Risk

The most critical restriction involves the risk of liver injury (hepatotoxicity). Regulatory authorities mandate that co-administration with any other medicinal product known to cause liver damage must be avoided. Similarly, the use of Flupirtine is contraindicated in patients with alcoholism, and co-administration with alcohol must generally be avoided due to the significantly increased risk to the liver.

Clinically Significant Interactions Requiring Monitoring

Interacting Agent	Official Regulatory Requirement
Oral Anticoagulants (e.g., Warfarin)	Flupirtine may potentiate the anticoagulant effects; blood coagulation times must be regularly monitored during co-treatment.
Paracetamol (Acetaminophen)	Co-administration has an increased potential for hepatotoxicity; hepatic transaminase levels must be monitored during concomitant use.

Pharmacodynamic and Metabolic Considerations

Sedative and Centrally Acting Medicines: Co-administration with agents like Benzodiazepines or other centrally acting medicines may result in potentiated tiredness and dizziness or increased sedative effects.
Carbamazepine: This combination is generally not advisable as Carbamazepine is a known hepatic enzyme inducer that can lead to altered clearance of Flupirtine.
Population-Specific Note: The interaction risk is more pronounced in patients with hepatic impairment. A mandatory dose reduction is required in this specific population to mitigate the exacerbation of potential interaction risks.

Mechanism of Action

Selective Activation of Neuronal Potassium Channels

The primary function of Flupirtine is to act as a Selective Neuronal Potassium Channel Opener (SNEPCO). It activates specific Kv7 potassium channels on nerve cell membranes, increasing the outward flow of K^+ ions. This action causes the cell to become hyperpolarized—more electrically stable—which directly dampens central neuronal over-excitability and stabilizes the primary nociceptive transmission neurons.

Dual Modulation: Nociceptive Pathways and Spinal Reflexes

The electrical stabilization achieved through potassium channel opening subsequently modulates two distinct physiological effects. Firstly, the hyperpolarization indirectly prevents the activation of NMDA receptors, thus inhibiting the flow of Ca^2+ ions and the transmission of nociceptive impulses in the spinal cord. Secondly, this central dampening effect extends to the motor system, inhibiting the hyperexcitable spinal reflex pathways that contribute to the regulation of skeletal muscle hypertonia.

Mechanistic Specificity and Functional Constraints

Flupirtine's mechanism is confined entirely to the central modulation of neuronal signaling; it is devoid of anti-inflammatory properties and does not interact with the peripheral processes mediated by inflammatory molecules like prostaglandins. Furthermore, its action is completely independent of opioid receptors, classifying its anti-nociceptive mechanism within a specific central pathway independent of the opioid system.

Dosage and Administration Information

The usage of Катадолон (Flupirtine) is governed by strict regulatory guidelines that define administration routes, specific dose limits, and mandatory restrictions on the duration of treatment, intended for use only as a short-term intervention. All instructions follow official prescribing information.

Administration Scope	Official Administration Guideline
Routes and Forms	Administered orally (as immediate-release capsules or modified-release tablets), rectally (as suppositories), or via intramuscular (i.m.) injection.
Dosing Schedule	Dosing must begin at the lowest effective dose. The standard adult daily maintenance range is typically 300 mg to 400 mg. The maximum daily dose officially allowed is 600 mg.
Frequency and Timing	Immediate-release forms are generally administered in divided doses, three to four times per day. The medicine may be taken with or without food. Oral forms must be swallowed whole and not crushed.
Treatment Duration	The duration of continuous oral or rectal treatment must not exceed 14 days (two weeks). The intramuscular solution is reserved for single-dose application.
Population Dosing Rules	Older Adults and Impairment: Patients with hepatic or renal impairment, or those who are elderly, require a mandatory 50% dose reduction. Children/Adolescents: The medicine must not be used in individuals under 18 years of age.

These usage principles ensure that the medicine is administered in a precise, time-restricted manner, strictly adhering to regulatory specifications regarding dosage and patient grouping. The strict maximum duration defines the short-term nature of its application, distinguishing it from long-term treatment protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Drug X for Condition A (Adults)

Research explored whether Drug X (flupirtine), when combined with standard care, was associated with a reduction in the symptoms of Condition A (e.g., moderate to severe acute or chronic pain) in adult patients. Studies evaluating flupirtine's use for various types of pain, including musculoskeletal pain, postoperative pain, and migraine, have been conducted.

Two Phase 3 randomized controlled trials (RCTs) evaluated whether this combination could be associated with a change in the intensity and occurrence of flare-ups in certain pain conditions like low back pain. Findings from pooled analyses of clinical trial data have suggested the analgesic effect of flupirtine was comparable to certain weak opioids and non-steroidal anti-inflammatory drugs (NSAIDs) in measured pain relief. Research also examined the tolerability of flupirtine compared to other treatments, suggesting it may be associated with a lower incidence of certain gastrointestinal and central nervous system adverse events.

Drug X for Condition A (Children and Adolescents)

Research has not widely established the use of flupirtine in children and adolescents, and evidence is currently more limited than for adults. Information regarding further investigation into this usage is ongoing.

Condition B (E.g., Muscle Relaxation)

In addition to its analgesic properties, flupirtine possesses effects consistent with skeletal muscle relaxation. Studies have evaluated this property, noting an association with reduced polysynaptic reflex activity. This effect is thought to contribute to its use in treating pain associated with increased muscle tension.

Safety Profile and Clinical Limitations

It is important to note that clinical data has provided evidence for an increased risk of hepatotoxicity (liver damage), including cases with fatal outcomes or those requiring liver transplantation, particularly when the duration of treatment is longer than two weeks. Consequently, regulatory bodies have implemented significant restrictions on its use and duration.

Key Studies & References Flupirtine as a Potential Treatment for Fibromyalgia (Review mentioning muscle relaxation and QoL studies)

Frequently Asked Questions (FAQ)

Common questions about Катадолон (FAQ)

Q: How quickly does Катадолон usually start working?

A: Official information suggests that pain relief is often observed within 1 to 2 hours after administration. Product documentation indicates this timeframe, though the full response can vary between individuals.

Q: How long does the effect of one dose of Катадолон typically last?

A: Regulatory information indicates that the pain-relieving effect of a single dose may last for up to 6 to 8 hours. The precise frequency of use is part of the professional prescribing guidance.

Q: Does using Катадолон affect driving or operating machinery?

A: This medicine may cause side effects such as dizziness and drowsiness. Official regulatory warnings state that if these side effects occur, activities such as driving or operating machinery should be avoided.

Q: Is it normal to feel dizzy when starting Катадолон?

A: Official safety documents classify dizziness as a very common or common side effect. Neurological effects are frequently reported by patients when treatment is initiated and may be self-limiting.

Q: What should be done if someone accidentally takes more Катадолон than usual?

A: Regulatory guidance on this medicine states that taking more than the prescribed amount needs to be managed as a medical emergency. Official guidance emphasizes that this situation requires management in a hospital setting.

Q: Can older adults (senior citizens) use Катадолон?

A: The medicine's use in older adults is conditional. According to official prescribing information, older adults, along with patients having renal or hepatic (liver) impairment, require a mandatory reduction in their prescribed dose.

Q: Does Катадолон affect sleep patterns?

A: Official safety documentation lists insomnia, or difficulty sleeping, as a common side effect that may be associated with the use of this medicine. This information is intended for educational purposes and does not replace the counsel of a medical professional.

Q: Can I take Катадолон if I have stomach issues or ulcers?

A: This medicine is not identified as having the same risk of causing gastrointestinal bleeding as certain traditional pain relievers. Furthermore, official instructions note the medicine may be taken with food to help mitigate potential gastrointestinal side effects such as nausea or vomiting.

Q: Do I need to take Катадолон with food?

A: The medicine may be taken with or without food. Taking it with food is sometimes advised as a measure to help mitigate potential gastrointestinal side effects.

Q: Does Катадолон lose effectiveness over time?

A: Regulatory and clinical trial summaries indicate that drug tolerance, which is a reduced effectiveness over time, does not develop in the majority of patients. However, this effect has been reported in isolated individual cases.

Q: What is the difference between Катадолон and regular painkillers like ibuprofen?

A: The active ingredient in Катадолон (Flupirtine) is a Centrally Acting Non-Opioid Analgesic. A key difference is that it does not have anti-inflammatory properties, unlike Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. It works through a unique mechanism on the central nervous system.

Q: Does Катадолон cause dependence or addiction?

A: This medicine is classified as a non-opioid analgesic, and physical dependence is considered uncommon. Despite this, limited reports suggest a potential for misuse or addiction liability in some vulnerable populations.

Q: What happens if I miss a dose of Катадолон?

A: Official patient information addresses the management of a missed dose by stating the general principle of skipping the missed dose when the next scheduled administration is close, in order to maintain the prescribed schedule.

Q: Is the active ingredient in Катадолон available under other names?

A: Yes, the active ingredient is Flupirtine maleate. This component is available under various brand names in different global markets.

Q: Is it true that Катадолон works differently than many common pain relievers?

A: Yes. It is the first in a unique class of analgesics (Selective Neuronal Potassium Channel Openers) that works by stabilizing the nerve cells that transmit pain signals in the central nervous system. This mechanism is distinct from both traditional NSAIDs and opioid medicines.

Q: Why is it sometimes described as a 'centrally acting' pain reliever?

A: It is referred to as 'centrally acting' because its mechanism of action is focused on the central nervous system, which includes the brain and spinal cord. It helps to stabilize the over-excitable nerve cells that are involved in pain transmission.

Q: Is Катадолон available without a prescription in some places?

A: Regulatory status in the markets where the medicine is approved generally classifies it as prescription-only. It is not intended for over-the-counter use.

Q: Can Катадолон cause constipation?

A: Constipation is a symptom that has been reported as a possible side effect of this medicine according to official regulatory documents.

Q: Are changes in mood or confusion a possible side effect of Катадолон?

A: Official regulatory documents list changes in mood states, specifically anxiety and depression, as uncommon side effects that may occur with the medicine.

Q: Is it possible to have a side effect that isn't listed in the official leaflet?

A: Regulatory documents acknowledge that new safety information may be identified over time, even after a medicine is approved. Healthcare professionals are therefore asked to report any suspected adverse reactions that are not yet listed in the official patient information.

Q: What studies exist regarding the long-term safety of Катадолон?

A: Research prior to regulatory restrictions did examine long-term use. However, clinical data indicating an increased risk of severe liver damage (hepatotoxicity) led regulatory bodies to mandate that treatment duration must not exceed 14 days.

Q: How is Катадолон eliminated from the body?

A: Pharmacokinetic data indicates that the body eliminates the medicine and its byproducts primarily through the urine (approximately 72%) and, to a lesser extent, through the feces (approximately 18%).

Q: Are there any specific monitoring tests required when taking Катадолон?

A: Mandatory liver function monitoring, such as weekly enzyme testing, is required throughout the course of treatment. Additionally, if the medicine is taken with oral anticoagulants, blood coagulation times must be regularly monitored.

Q: Does Катадолон interact with common cold or flu medications?

A: Regulatory guidance mandates avoiding co-administration with any other medicinal product known to cause liver injury. This mandates consideration of the composition of common cold and flu medications, as many contain paracetamol (acetaminophen).

Q: Is Катадолон used for headaches or migraines?

A: Studies have examined the medicine's use for various types of pain, including tension headaches and migraines. The approved indication is generally restricted to the treatment of acute pain in adults.

Q: Can I stop taking Катадолон suddenly?

A: Physical dependence is considered uncommon. However, withdrawal symptoms, such as anxiety, insomnia, or tremors, have been reported in isolated cases following the abrupt cessation of the medicine.

Q: Do studies suggest Катадолон is useful for nerve pain?

A: Studies have examined the medicine's use for pain that includes neuralgias and neuropathic pain, which aligns with its central mechanism of action on the nervous system. The currently approved indication is restricted to acute pain in adults.

How should Катадолон be stored and disposed of?

How to Store and Dispose of Катадолон?

The official storage and disposal requirements for Катадолон (Flupirtine) are defined by regulatory standards to maintain product integrity and environmental safety.

Official Storage Conditions

Storage Requirement	Rule
Temperature	Store at a controlled temperature, not exceeding 30 C.
Protection	Must be kept in a dry and dark place, protected from light and moisture.
Packaging	Store only in the original container, ensuring it remains tightly closed.

Safety and Disposal Mandates

All medicines, including Катадолон, must be kept out of the sight and reach of children at all times. Disposal rules prohibit throwing unused or expired medicine into household trash or flushing it down the toilet or drain. Disposal must follow local, regional, and national regulations for pharmaceutical waste, often through authorized drug take-back programs.

Катадолон